Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EXPOSURE study of edoxaban in porto-sinusoidal vascular disorder
2024-513353-73-00Phase 2Authorised
- Sponsor
- Medical University of Vienna
- Start
- Apr 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of edoxaban in Porto-sinusoidal vascular disease (PSVD) (2 arms), sponsored by Medical University of Vienna. Primary endpoint: Incidence of major bleeding. Planned start Apr 2025; status: authorised.
02
Drugs
edoxaban
03
Conditions
Porto-sinusoidal vascular disease (PSVD)
Beyond the preview
Go deeper on 2024-513353-73-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-513353-73-00.